SUPN: Supernus Pharmaceuticals, Inc. Stock

by  •  • Comments Off on SUPN: Supernus Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2,062.99
Enterprise Value ($M) 2,031.32
Book Value ($M) 1,007.15
Book Value / Share 18.24
Price / Book 2.05
NCAV ($M) 304.45
NCAV / Share 5.51
Price / NCAV 6.78

Profitability (mra)
Return on Invested Capital (ROIC) 0.06
Return on Assets (ROA) 0.05
Return on Equity (ROE) 0.06

Liquidity (mrq)
Quick Ratio 1.98
Current Ratio 2.20

Balance Sheet (mrq) ($M)
Current Assets 640.00
Assets 1,342.70
Liabilities 335.55
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Armistice Capital, Llc 9.25 9.59
11-01 13G/A Macquarie Group Ltd 4.78 -3.87
10-31 13G Dimensional Fund Advisors Lp 5.20
02-13 13G/A Vanguard Group Inc 11.38 7.34
2024-01-19 13G/A BlackRock, Inc. 19.00 8.09

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2023 or ☐ TRANSMISSION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 98,368 523,258 18.80
2025-02-03 167,702 714,497 23.47
2025-01-31 61,399 213,780 28.72
2025-01-30 31,129 195,339 15.94

(click for more detail)

Similar Companies
SMMT – Summit Therapeutics Inc. SPRY – ARS Pharmaceuticals, Inc.
STRO – Sutro Biopharma, Inc. TARA – Protara Therapeutics, Inc.
TBPH – Theravance Biopharma, Inc.


Financial data and stock pages provided by
Fintel.io